Ionis Pharmaceuticals Stock Performance
| IONS Stock | USD 33.16 0.25 0.76% |
The company retains a Market Volatility (i.e., Beta) of 0.99, which attests to possible diversification benefits within a given portfolio. Ionis Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Ionis Pharmaceuticals is expected to follow. At this point, Ionis Pharmaceuticals has a negative expected return of -0.13%. Please make sure to check out Ionis Pharmaceuticals' jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to decide if Ionis Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Ionis Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return 0.55 | Five Day Return 0.0912 | Year To Date Return (5.13) | Ten Year Return (51.76) | All Time Return 229.1 |
1 | Acquisition by Baroldi Joseph of 2500 shares of Ionis Pharmaceuticals at 34.69 subject to Rule 16b-3 | 01/02/2025 |
2 | Acquisition by Bennett C Frank of 3607 shares of Ionis Pharmaceuticals subject to Rule 16b-3 | 01/30/2025 |
3 | Disposition of 1406 shares by Oneil Patrick R. of Ionis Pharmaceuticals at 32.4926 subject to Rule 16b-3 | 02/03/2025 |
4 | Ionis Pharmaceuticals, Inc. Q4 2024 Earnings Call Transcript | 02/20/2025 |
5 | Ionis Pharmaceuticals Inc Announces Participation in Upcoming Investor Conferences | 02/25/2025 |
6 | Theratechnologies Inc Q4 2024 Earnings Call Highlights Strong EBITDA Turnaround and ... | 02/27/2025 |
7 | Acquisition by Bennett C Frank of 320 shares of Ionis Pharmaceuticals at 28.2115 subject to Rule 16b-3 | 02/28/2025 |
8 | Disposition of 12295 shares by Devers Shannon L. of Ionis Pharmaceuticals subject to Rule 16b-3 | 03/03/2025 |
9 | Acquisition by Devers Shannon L. of 22000 shares of Ionis Pharmaceuticals at 34.69 subject to Rule 16b-3 | 03/04/2025 |
10 | Disposition of 140 shares by Brett Monia of Ionis Pharmaceuticals at 32.32 subject to Rule 16b-3 | 03/11/2025 |
11 | Ionis inks licensing deal with Ono | 03/12/2025 |
12 | Why Is Ionis Pharmaceuticals Up 0.1 percent Since Last Earnings Report | 03/21/2025 |
| Begin Period Cash Flow | 399.3 M |
Ionis |
Ionis Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 3,653 in Ionis Pharmaceuticals on December 24, 2024 and sell it today you would lose (337.00) from holding Ionis Pharmaceuticals or give up 9.23% of portfolio value over 90 days. Ionis Pharmaceuticals is currently does not generate positive expected returns and assumes 2.5707% risk (volatility on return distribution) over the 90 days horizon. In different words, 22% of stocks are less volatile than Ionis, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Ionis Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ionis Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Ionis Pharmaceuticals, and traders can use it to determine the average amount a Ionis Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0491
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IONS |
Estimated Market Risk
| 2.57 actual daily | 22 78% of assets are more volatile |
Expected Return
| -0.13 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Ionis Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Ionis Pharmaceuticals by adding Ionis Pharmaceuticals to a well-diversified portfolio.
Ionis Pharmaceuticals Fundamentals Growth
Ionis Stock prices reflect investors' perceptions of the future prospects and financial health of Ionis Pharmaceuticals, and Ionis Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ionis Stock performance.
| Return On Equity | -0.93 | ||||
| Return On Asset | -0.0991 | ||||
| Profit Margin | (0.64) % | ||||
| Operating Margin | (0.49) % | ||||
| Current Valuation | 4.35 B | ||||
| Shares Outstanding | 158.96 M | ||||
| Price To Earning | 101.16 X | ||||
| Price To Book | 8.89 X | ||||
| Price To Sales | 7.42 X | ||||
| Revenue | 705.14 M | ||||
| Gross Profit | (207.61 M) | ||||
| EBITDA | (475.08 M) | ||||
| Net Income | (453.9 M) | ||||
| Cash And Equivalents | 2.04 B | ||||
| Cash Per Share | 14.36 X | ||||
| Total Debt | 1.41 B | ||||
| Debt To Equity | 2.00 % | ||||
| Current Ratio | 8.18 X | ||||
| Book Value Per Share | 3.73 X | ||||
| Cash Flow From Operations | (500.95 M) | ||||
| Earnings Per Share | (3.04) X | ||||
| Market Capitalization | 5.23 B | ||||
| Total Asset | 3 B | ||||
| Retained Earnings | (2.25 B) | ||||
| Working Capital | 2.31 B | ||||
| Current Asset | 837 M | ||||
| Current Liabilities | 148.88 M | ||||
About Ionis Pharmaceuticals Performance
Assessing Ionis Pharmaceuticals' fundamental ratios provides investors with valuable insights into Ionis Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Ionis Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 407.21 | 434.09 | |
| Return On Tangible Assets | (0.15) | (0.16) | |
| Return On Capital Employed | (0.18) | (0.19) | |
| Return On Assets | (0.15) | (0.16) | |
| Return On Equity | (0.77) | (0.81) |
Things to note about Ionis Pharmaceuticals performance evaluation
Checking the ongoing alerts about Ionis Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Ionis Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Ionis Pharmaceuticals generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 705.14 M. Net Loss for the year was (453.9 M) with loss before overhead, payroll, taxes, and interest of (207.61 M). | |
| Ionis Pharmaceuticals currently holds about 2.04 B in cash with (500.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.36. | |
| Ionis Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from zacks.com: Why Is Ionis Pharmaceuticals Up 0.1 percent Since Last Earnings Report |
- Analyzing Ionis Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ionis Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Ionis Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ionis Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ionis Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Ionis Pharmaceuticals' stock. These opinions can provide insight into Ionis Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Ionis Stock Analysis
When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.